The use of selective inhibition of TNF-R2 with a soluble TNF-R2 fusion protein (etanercept) has also been associated with the manifestation of MS-like demyelinating lesions due to the blockade of both sTNF and mTNF, confirming the idea that mTNF probably has a dominant role in the regenerative process and resolution of inflammation [33]. Here, TNFRSF1B is linked to myeloid sarcoma.